glp-1 news 2025 november Receptor Agonist Market Valued at USD 62.86 Billion in 2025, Set to Grow at 17.5% CAGR Through 2034 GLP-1 makers could be under

Different types of protein provide different benefits, said Corbion's Beech

Other times, weight loss is not long-term, as weight gain quickly resumes after people stop taking the medication

While more research is needed, these findings suggest a promising avenue for those with chronic conditions

Remaining Scope for Side-Effect Improvement Retatrutide is a triple-action therapy that, like Lillys Mounjaro and Zepbound drugs, targets glucagon-like peptide-1, or GLP-1, and glucose-dependent insulinotropic polypeptide, or GIP, while also acting on the glucagon receptor

Semaglutide in patients with heart failure with preserved ejection fraction and obesity